Intuitive Surgical Inc
- 거래소
- 미국
- 국가 / 지역
- USA
- 상장일
- 2000년 6월 13일
- 직원 수
- 17,021
종합 밸류에이션 구간 · 보수적 $220–$300 / 적정 $300–$380 / 낙관적 $380–$430. $356.83 기준, 적정 내재가치 구간 내.
보고서 발행 시 $439.8（2026년 5월 22일）
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
연혁
Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California. It completed its IPO on June 13, 2000. The company commercialized the da Vinci Surgical System for minimally invasive surgery and later extended beyond surgery with the Ion endoluminal system, which enables minimally invasive lung biopsies. It is currently rolling out its next-generation da Vinci 5 platform globally.
업계 내 위치
Intuitive Surgical is a Healthcare-sector company in Medical Instruments & Supplies and the leader in robotic-assisted surgery. In 2025 total revenue was USD 10.065B, split into instruments & accessories USD 6.019B, systems USD 2.474B, and service USD 1.572B. Its da Vinci installed base reached about 11,106 systems at the end of 2025 (about 11,395 by 2026Q1), with about 995 Ion systems installed. Named competitors include Johnson & Johnson, Medtronic, CMR Surgical, MicroPort MedBot, and Karl Storz. The company has 17,021 employees, over 5,600 active patents, and spent USD 1.312B on R&D in 2025.
이 종목에 대한 리포트가 아직 해당 언어로 없습니다.